These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30596643)

  • 41. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.
    van der Haar Àvila I; Marmol P; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():167-179. PubMed ID: 30666606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
    Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
    Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.
    Xu F; Sunderland A; Zhou Y; Schulick RD; Edil BH; Zhu Y
    Cancer Immunol Immunother; 2017 Oct; 66(10):1367-1375. PubMed ID: 28623459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme.
    Kawaguchi Y; Kono K; Mizukami Y; Mimura K; Fujii H
    Anticancer Res; 2009 Jun; 29(6):2137-46. PubMed ID: 19528474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Precision glycocalyx editing as a strategy for cancer immunotherapy.
    Xiao H; Woods EC; Vukojicic P; Bertozzi CR
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10304-9. PubMed ID: 27551071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
    Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
    Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
    Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
    Mimura K; Kono K; Hanawa M; Kanzaki M; Nakao A; Ooi A; Fujii H
    Clin Cancer Res; 2005 Jul; 11(13):4898-904. PubMed ID: 16000588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
    Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
    Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
    Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
    Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
    Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
    J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.